The latest announcement is out from Eliem Therapeutics (ELYM).
Aoife Brennan has been appointed as the President and CEO of Eliem, and will serve as a member of the board until the 2027 annual stockholders meeting. Bringing extensive biotech management experience and a notable track record from her previous roles at Synlogic, Inc. and Biogen Inc., where she led the approval of several major drugs, Dr. Brennan is well-positioned to steer Eliem through its next phases of growth. Her compensation includes a $650,000 base salary, potential bonuses, stock options, and other benefits. Additionally, Stephen Thomas, CEO of Tenet, has been elected to Eliem’s board, with expectations of further contribution as a consultant post-Acquisition. These strategic appointments come amidst Eliem’s significant acquisition activities and are critical for investors monitoring the company’s leadership and direction.
Learn more about ELYM stock on TipRanks’ Stock Analysis page.